Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.014
Sell
RSI(14)
39.301
Neutral
STOCH(KDJ)(9,3,3)
16.839
Sell
ATR(14)
0.264
Low Volatility
CCI(14)
-88.675
Neutral
Williams %R
71.053
Sell
TRIX(12,20)
-0.389
Sell
StochRSI(14)
0.000
Oversold
Search
Passage Bio Inc
PASGAdd to Watchlist
4.470USD
-0.020-0.45%
Close 07-31 16:00（ET）Quotes delayed by 15 min
14.23MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-0.45%
5 Days
-9.51%
1 Month
-8.40%
6 Months
-61.13%
Year to Date
-62.12%
1 Year
-30.37%
Key Figures
4.530Open
4.616High
4.98KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.16%Turnover Ratio
4.490Prev. Close
4.470Low
18.54KTurnover
LossP/E Static
0.76P/B
0.00%Div Yield TTM
-61.53%ROA
20.00052wk High
0.16Volume Ratio
-64.77MNet Profit
3.18MShares
-11.7445EPS TTM
1.40Beta
-128.90%ROE
3.93552wk Low
3.24%Amplitude
--Gross Margin
14.23MMarket Cap
-0.63Reward/Risk
6.47%Risk Rate
Passage Bio Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
3
analysts
Hold
Current Rating
15.500
Target Price
+242.92%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Passage Bio Inc
PASG
3
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
4.534
Sell
MA10
4.715
Sell
MA20
4.725
Sell
MA50
5.144
Sell
MA100
6.091
Sell
MA200
8.007
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Passage Bio Inc Info
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Ticker SymbolPASG
CompanyPassage Bio Inc
CEOChou (William)
Websitehttps://www.passagebio.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Passage Bio Inc (PASG)?
The current price of Passage Bio Inc (PASG) is 4.55.
What is the symbol of Passage Bio Inc?
The ticker symbol of Passage Bio Inc is PASG.
What is the 52-week high of Passage Bio Inc?
The 52-week high of Passage Bio Inc is 20.00.
What is the 52-week low of Passage Bio Inc?
The 52-week low of Passage Bio Inc is 3.94.
What is the market capitalization of Passage Bio Inc?
The market capitalization of Passage Bio Inc is 14.48M.
Is Passage Bio Inc (PASG) currently rated as Buy, Hold, or Sell?
According to analysts, Passage Bio Inc (PASG) has an overall rating of signal_hold, with a price target of 15.50.
What is the Earnings Per Share (EPS TTM) of Passage Bio Inc (PASG)?
The Earnings Per Share (EPS TTM) of Passage Bio Inc (PASG) is -14.35.